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Abstract 
Levels of serum amyloid A (SAA), a major acute phase protein in humans, are increased up to 
1000-fold upon infection, trauma, cancer or other events causing inflammation. However, 
the exact role of SAA in host defense is yet not fully understood. Several pro- and anti-
inflammatory properties have been ascribed to SAA. Here, the regulated production of SAA 
by cytokines and glucocorticoids is discussed first. Secondly, the cytokine and chemokine 
inducing capacity of SAA and its receptor usage are reviewed. Thirdly, the direct and indirect 
chemotactic effects of SAA and its synergy with chemokines are unraveled. Altogether, this 
review provides evidence for the establishment of a complex cytokine-SAA-chemokine 
network, in which SAA plays a key role in regulating the inflammatory response. 
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1. Introduction 
During inflammatory events, such as infection, trauma and neoplasia, the acute phase 
response is initiated to eliminate pathogens and to restore homeostasis without causing too 
much damage to the organism. This acute phase response is characterized by a wide range 
of systemic and metabolic changes (e.g. fever, leukocytosis, altered plasma levels of minerals 
and vitamins), including the induction of acute phase proteins (e.g. serum amyloid A, C-
reactive protein) in the liver [1, 2]. In humans, serum amyloid A (SAA) is one of the major 
acute phase proteins and consists of SAA1, SAA2, SAA3 and SAA4. SAA1 (with the isoforms 
SAA1α, -β and -γ) and SAA2 (with the isoforms SAA2α and -β) are also designated “acute 
phase SAA” (A-SAA), since the serum concentration of these SAA types increases up to 1000-
fold during the acute phase response. Once secreted in the blood circulation, A-SAA binds to 
high density lipoprotein (HDL), thereby displacing apolipoprotein (Apo)-A-I. Although SAA3 is 
predominantly expressed extrahepatically in other mammals [3], it was detected only at very 
low concentrations in humans [4]. In contrast to A-SAA, SAA4 is constitutively present in the 
blood circulation [5]. For that reason, SAA4 is also denominated “constitutive SAA” (C-SAA). 
Until now, several functions have been attributed to SAA, such as antimicrobial 
activities and the induction of matrix degrading enzymes (e.g. MMP-9) [6-10]. However, the 
complete role of this highly conserved acute phase protein has not yet been elucidated. Part 
of its pro-inflammatory capacities resides in its ability to induce cytokines and chemokines 
and to exert direct chemotactic activity via its receptors, predominantly TLR2 and FPR2, 
respectively. 
In this survey, the regulated production of A-SAA by (anti-)inflammatory agents, its 
cytokine and chemokine inducing activity, as well as its chemotactic effect will be reviewed. 
Since the liver is the primary source of this acute phase protein [2, 11, 12], the induction of 
A-SAA in human hepatocytes by cytokines and glucocorticoids will be discussed first. 
2. Regulated production of acute phase SAA in the liver 
2.1. Induction of A-SAA by cytokines 
The induction of SAA mRNA and/or protein in primary hepatocytes and hepatoma cell lines 
in vitro is summarized in Table 1. Some of these data are contra-intuitive, for instance, 
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although known to be major inducers of acute phase proteins in the liver, IL-1β or IL-6 alone 
did not always induce SAA expression in vitro [13-20]. In general, in hepatoma cell lines, IL-6 
stimulates the induction of SAA to a lesser extent than IL-1 [20-23]. TNF-α is a weak SAA-
inducer in hepatocytes (Table 1). Only Thorn et al. [18] detected induction of SAA when 
HepG2 cells were stimulated with TNF-α alone. IL-1 is the strongest inducer of SAA mRNA 
and protein, with IL-1β being more potent than IL-1α [22, 24]. 
 In contrast to the sometimes weak in vitro induction rate of SAA when IL-1, IL-6 and 
TNF-α were used separately to stimulate hepatocytes or hepatoma cells, these cytokines 
were able to cooperate or even synergize to greatly enhance the production of SAA [14, 15, 
18-21, 23, 25]. In fact, in vivo, IL-1 stimulates the production of IL-6 in several cell types, 
thereby directly and indirectly amplifying the synthesis of acute phase proteins in the liver 
[26]. In all the studies, where IL-6 alone did not induce SAA, this cytokine synergized with IL-
1 to increase the expression the SAA gene in hepatoma cells [14, 20, 23, 25]. Moreover TNF-
α, which is often a poor inducer of SAA, potentiated the effect of IL-6 [14, 18, 19]. However, 
Vreugdenhil et al. [25] reported that TNF-α inhibited the IL-1β- or IL-1β plus IL-6-induced 
SAA production in HuH7 hepatoma cells. Nonetheless, no other data are available about the 
effect of TNF-α on the induction of SAA in HuH7 cells; additional studies are required to draw 
firm conclusions. 
 The kinetics of SAA induction seem to depend on the cytokine stimulating the 
synthesis of SAA. IL-6 induced a maximal production of SAA2 mRNA in HepG2 hepatoma cells 
as early as 3 h post induction, whereas maximal amounts of SAA2 mRNA were only produced 
after 12 to 24 h when the cells were treated with IL-1β or TNF-α [19]. Secondly, Thorn and 
Whitehead [16] and Thorn et al. [17] stipulated that the cytokine type determines which A-
SAA form is preferably induced. These authors showed that, besides SAA1 mRNA, 
particularly SAA2 mRNA was induced in HepG2 cells upon stimulation with IL-1 and/or IL-6 or 
with a combination of IL-6 and TNF-α. Furthermore, the production level of SAA after 
stimulation of Hep3B and HepG2 cells with a combination of IL-1 and IL-6 depended on the 
cytokine concentration. SAA synthesis dose-dependently increased with increasing 
concentrations of one of both cytokines, as long as the other cytokine was present at 
minimal concentrations [14, 22]. Finally, the order of addition of the cytokines to the cells is 
important for the level of SAA synthesis, since Thorn et al. [18] found that there was a better 
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induction of A-SAA mRNA when HepG2 cells were treated with TNF-α and subsequently with 
IL-6, rather than vice versa. 
2.2. Induction of A-SAA by glucocorticoids 
Glucocorticoids down-regulate the synthesis of IL-1, IL-6 and TNF-α [12, 22, 27]. On the other 
hand, these anti-inflammatory agents also directly stimulate the production of some acute 
phase proteins, including SAA. The glucocorticoid receptor-ligand complex translocates to 
the nucleus, where it functions as a transcription factor, up-regulating the transcription of 
acute phase genes [12, 27]. 
In contrast to their effects in some non-hepatic cell lines [17, 18, 28-33], 
glucocorticoids (mostly studied using the synthetic glucocorticoid dexamethasone) on their 
own did not induce SAA production in hepatocytes or hepatoma cell lines [14, 20-22, 33-35]. 
However, glucocorticoids were shown to be potent enhancers of SAA induction in 
hepatocytes and hepatoma cells when combined with IL-1 and/or IL-6 [14, 17, 20-22, 33, 36]. 
No cooperation between TNF-α and dexamethasone was found in HepG2 hepatoma cells, 
but this combination has so far been studied poorly [22]. Synergy between glucocorticoids 
and TNF-α to induce SAA, as well as between glucocorticoids and the other cytokines, was 
nonetheless already evidenced in several non-hepatic cell lines [17, 18, 25, 28, 31]. Even 
more, dexamethasone was found to be necessary to induce SAA in smooth muscle cells, 
multipotent adipose-derived stem cells and monocytic THP-1 cells, stimulated with 
inflammatory agents such as IL-1, IL-6 or lipopolysaccharide (LPS) [32, 37, 38]. This effect was 
not observed in hepatocytes. 
When glucocorticoids associate with their receptor, this receptor-ligand complex 
binds as a transcription factor to a glucocorticoid response element (GRE; 
GGCACATCTTGTTCC) in the promotor of certain genes. Concerning the different A-SAA 
genes, a GRE is present only in the SAA1 promotor, but not in the promotor of the SAA2 
gene. This explains why only the transcription of the SAA1 gene massively increased when 
hepatoma cells or cells of the oral epidermal carcinoma cell line KB were treated with a 
combination of dexamethasone and cytokines (alone or in combination). As a consequence, 
the SAA1 level was specifically augmented in contrast to the amount of SAA2, whereas the 
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equilibrium between the transcription of both A-SAA genes was opposite when the cells 
were stimulated with cytokines without dexamethasone [16-18]. 
2.3. Induction of A-SAA by toll-like receptor ligands 
Direct induction of A-SAA by toll-like receptor (TLR) ligands in humans has until now only 
been shown for LPS, originating from the outer membrane of gram-negative bacteria. In 
contrast to mice [12], LPS-mediated induction of A-SAA has not yet been intensively studied 
in humans, except for some human cell lines in which LPS has been used as an SAA inducer. 
Ray and Ray [39] and Bozinovski et al. [28] demonstrated the expression of SAA mRNA in 
undifferentiated THP-1 cells treated with LPS. In addition, LPS and dexamethasone 
synergized strongly for inducing SAA mRNA [28, 38]. 
2.4. (Post-)transcriptional and (post-)translational regulation of A-SAA synthesis 
Under inflammatory conditions, macrophages and other leukocytes produce large amounts 
of IL-1, IL-6 and TNF-α. Binding of these cytokines to their proper receptors triggers the 
activation of different intracellular signal transduction pathways, leading eventually to the 
activation of several transcription factors in the cytoplasm, mostly via phosphorylation 
events. For cytokine-induced production of A-SAA in humans, four transcription factors are 
important: NF-κB, activated by IL-1 and TNF, NF-IL6 [human orthologue of C/enhancer 
binding protein (EBP) in other species], activated by IL-1 and IL-6, NF-IL6β, activated by 
phosphorylated (i.e. activated) NF-IL6, and SAA activating sequence (SAS) activating factor 
(SAF), activated by IL-6 and LPS [12, 27, 39-46]. Binding of these transcription factors to 
regulatory elements in the A-SAA promotor results in transcription of A-SAA mRNA. In rats, 
an additional transcription factor, YY1, which inhibits the transcription of the SAA1 gene, was 
found. Two potential YY1-binding sites have been found in the promotor of the human SAA2 
gene, but the significance of this negative regulator has not yet been elucidated in humans 
[27]. Nonetheless, Edbrooke et al. [47] detected a negative NF-κB-binding element in the 
human A-SAA promotor, i.e. SAAκB2. Mutation of this binding site, resulting in disabled 
binding of NF-κB, caused a higher transcription rate of C-SAA and of IL-1-induced SAA. 
Further research about these negative regulating binding sites is required. 
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 The production of A-SAA is not only regulated at the transcriptional level, but also at 
the post-transcriptional stage. This was demonstrated in cytokine-stimulated hepatoma 
Hep3B cells by Jiang et al. [15, 48], who found a discrepancy between transcriptional activity 
of the SAA gene(s) and the actual SAA mRNA levels detected, the latter being relatively high. 
Moreover, treatment of hepatoma PLC/PRF/5 cells, KB (epithelial) cells or ECV304 
(endothelial) cells with the transcription inhibitor actinomycin D did not diminish A-SAA 
mRNA levels, suggesting that the mRNA becomes stabilized. However, this phenomenon 
does not occur via inhibition of poly(A)tail shortening, since the stability of SAA mRNA with 
different lengths of the poly(A)tail was identical in PLC/PRF/5 cells [33, 35].  
Besides transcriptional and post-transcriptional control of A-SAA gene expression, 
there is also evidence of translational regulation of this gene. Despite of high A-SAA mRNA 
levels in PLC/PRF/5 cells, secretion of the protein itself was relatively low [35]. No 
explanation for this discrepancy was found. In fact, there was neither a change in A-SAA 
mRNA polyribosome association, nor a decline in export time of the protein. More studies 
are needed to unravel the post-transcriptional and potential (post-)translational regulation 
of the SAA genes. In contrast, several post-translationally modified SAA forms have been 
detected in deposits of amyloid A fibrils, causing amyloid A amyloidosis [49]. 
3. The SAA-chemokine cascade 
3.1. SAA as a cytokine inducer 
3.1.1. Induction of cytokines by SAA 
As illustrated in Table 2, many cytokines are produced by SAA-stimulated cells. Members of 
different cytokine families can be induced. Induction of cytokines belonging to the 
chemokine family is discussed in a separate section (vide infra). 
IL-1β, IL-6 and TNF-α are the most extensively studied cytokines to be induced by 
SAA. Maximal production of IL-1β after 18 h to 24 h stimulation of cells with SAA did 
generally reach not more than 1 ng/ml [50-54]. Often relatively high concentrations (1-10 
µg/ml) of SAA (in comparison to IL-1β induction by LPS) were needed to significantly induce 
this cytokine in monocytes, macrophages, synoviocytes and keratinocytes [51, 52, 54-57]. IL-
1β was only induced by high concentrations (≥ 100 µg/ml) of SAA in neutrophils and HMC-1 
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mast cells [50, 58]. Niemi et al. [58] and Yu et al. [54] evidenced that SAA stimulated IL-1β 
production by binding to TLR2 and TLR4 expressed on macrophages and keratinocytes, since 
incubation of these cells with anti-TLR2 or anti-TLR4 antibodies significantly reduced the 
expression of IL-1β mRNA by SAA (Table 2). Moreover, when the cells were treated with a 
combination of both antibodies, the IL-1β mRNA expression further decreased. In contrast, 
treatment of the cells with pertussis toxin, which binds Gαi and prevents G protein subunit 
dissociation, or with anti-cluster of differentiation (CD)36 antibody did not affect mRNA 
expression by SAA. This indicates that the GPCR formyl peptide receptor like 1/formyl 
peptide receptor 2 (FPRL1/FPR2) and CD36 are not involved in IL-1β induction by SAA in 
these cells. CD36 is a member of the class B scavenger receptor family binding LDL and has 
been shown to mediate induction of chemokines by SAA (vide infra). In contrast to IL-1β, 
induction of IL-33 involves binding to FPR2 in addition to TLR2. Besides significant inhibition 
of IL-33 production in peritoneal macrophages of TLR2 knockout mice, IL-33 production in 
peritoneal macrophages of FPR2-depleted mice was also inhibited for 50%, compared to 
normal mice [59]. 
 SAA also stimulated the production of IL-6. Levels ranging from less than 1 ng/ml in 
primary dermal fibroblasts [60] and 3-5 ng/ml in endothelial cells [61, 62] up to 25-70 ng/ml 
in synovial fibroblasts and chondrocytes [29, 42] were detected after 24 h stimulation. Like 
for IL-1β induction, a relatively high (about 0.5-10 µg/ml) SAA concentration (in comparison 
to IL-6 induction by LPS and IL-1β) was required to induce IL-6. Different receptors have been 
proposed for the induction of the production of IL-6 by SAA: TLR2, TLR4 and CLA-1 (CD36 and 
LIMP II analogous-1). CLA-1 is the human orthologue of the murine scavenger receptor class 
B type I (SR-BI) and binds, besides density lipoproteins, a variety of ligands [63, 64]. Both 
anti-TLR2 antibody and small interfering (si)RNA, knocking down TLR2, significantly inhibited 
IL-6 induction in SAA-stimulated fibroblasts [60]. Lakota et al. [61] also observed an 
inhibition of IL-6 induction by TLR2-targeted siRNA in endothelial cells, but this decline in IL-6 
production was not significant. Mullan and co-workers [62] showed that the induction of IL-6 
diminished clearly in synovial fibroblasts from three out of four rheumatoid arthritis (RA) 
patients upon treatment of the cells with anti-(murine) SR-BI antibody that also inhibited 
(human) CLA-1, suggesting the involvement of CLA-1 in cytokine induction by SAA in certain 
cases. Nonetheless, de Seny et al. [29] did not see any effect on SAA-induced IL-6 production 
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in synovial fibroblasts or in human primary chondrocytes from osteoarthritis patients neither 
using an anti-SR-BI antibody, nor using the irreversible CD36 inhibitor SSO or an antibody 
against receptor for advanced glycation end products (RAGE), shown to mediate the SAA-
induced production of tissue factor in monocytes [65]. Furthermore, competition with 
lipoxin A4 for binding to FPR2 did not reduce IL-6 production. On the other hand, these 
authors demonstrated that the IL-6 induction in synovial fibroblasts and primary 
chondrocytes from osteoarthritis patients was triggered by binding of SAA to TLR4 [29]. 
In contrast to the SAA-induced production of IL-1β, that of TNF-α seemed to be 
highest at 18 h post stimulation and was already declining at 24 h. At 18 h, supernatants 
from cell cultures of neutrophils, monocytes or macrophages contained 5-20 ng/ml TNF-α 
[51, 52], whereas there was only 2-5 ng/ml left at 24 h [50, 66-69]. Just as for IL-1β and IL-6, 
TNF-α was significantly induced in these cells by SAA at relatively high concentrations (from 
1.25-10 µg/ml onwards). Mast cells needed to be stimulated with a high concentration (120 
µg/ml) of SAA to produce TNF-α [58]. Furthermore, monocytes and macrophages tended to 
produce more TNF-α than neutrophils in response to SAA. With regard to the receptor 
mediating the induction of TNF-α by SAA, Chen et al. [69] found a slight, but significant 
inhibition of TNF-α production when macrophages were preincubated with anti-TLR2 
antibody. Nonetheless, the involvement of other putative receptors has still to be 
investigated. 
 Induction of ‘other’ cytokines than IL-1β, IL-6 or TNF-α by SAA was less studied. It is 
worth mentioning that SAA stimulates the induction of active IL-23 (consisting of the IL-
12p40 and the IL-23p19 subunits), but not of IL-12 (consisting of the IL-12p40 and the IL-
12p35 subunits), since it induces only the IL-12p40 [56, 70] and the IL-23p19 [55, 56, 70] 
subunits, but not the IL-12p35 subunit [70]. TLR2 has regularly been mentioned as a 
signaling receptor for SAA-induced production of cytokines (Table 2). Induction of GM-CSF 
and the anti-inflammatory cytokine IL-10 in endothelial cells and macrophages, respectively, 
diminished significantly upon treatment of cells with anti-TLR2 antibody or with siRNA for 
TLR2 [61, 69]. FPR2 was shown to be involved in the SAA-mediated induction of GM-CSF, M-
CSF and IL-10 in A549, HepG2 and U937 cells, respectively [28, 55]. Since knocking down 
FPR2 via treatment of cells with the FPR2 antagonist WRW4 or with short hairpin RNA 
partially inhibited M-CSF and IL-10 induction (40% and 60% inhibition, respectively) [55], one 
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must indeed conclude that multiple receptors are involved in SAA-mediated cytokine 
induction. 
3.1.2. Induction of chemokines by SAA 
SAA induces the production of CC and CXC chemokines in different cell types (Table 3). The 
production of the inflammatory chemokines CCL2 and CXCL8 has been investigated in detail 
and will be discussed hereafter. 
The induction of CCL2 after stimulation with SAA has mostly been investigated in 
monocytes and endothelial cells. In monocytes, the highest CCL2 production (20-25 ng/ml) 
was seen 24 h after stimulation with SAA [53, 71]. At a concentration as low as 25 ng/ml, 
SAA was already able to induce a significant amount of CCL2 in these cells [71]. CCL2 
production in SAA-treated (6-25 µg/ml) endothelial cells reached levels of 20-60 ng/ml 24 h 
post stimulation [72-74]. Significant levels of CCL2 (10-35 ng/ml) were already induced at 4-8 
h after treatment of endothelial cells with SAA [71, 74, 75]. 
Although for the induction of cytokines, SAA has been reported to signal mostly via 
TLRs and less via FPR2, the induction of CCL2 was found to be mainly mediated by FPR2 [28, 
55, 71, 73, 74]. Bozinovski and co-workers [28] found that human FPR2-transfected A549 
lung epithelial cells produced three times more CCL2 (90 ng/ml) upon stimulation with SAA 
(1 mg/ml) than when cells were treated with vehicle (30 ng/ml). Moreover, the induction of 
CCL2 was completely inhibited in monocytes and endothelial cells using the FPR2 antagonist 
WRW4 [71, 74]. Partial (but significant) inhibition (about 50%) of CCL2 production was 
observed in endothelial cells transfected with FPR2 siRNA [73], as well as in HepG2 cells 
transfected with FPR2 short hairpin RNA (35% inhibition) [55]. Connolly et al. [72] 
demonstrated that CCL2 production under influence of endogenously produced SAA in 
synovial explant cultures minimally diminished (from 9 to 6.5 ng/ml) upon competition for 
binding to FPR2 with lipoxin A4. These data and related results on the induction of some 
cytokines suggest that other receptors are also involved in SAA-mediated CCL2 production. 
Indeed, a minimal but significant inhibition of CCL2 production (from 8.5 to 6 ng/ml after 24 
h stimulation) was detected when synovial explant cultures were treated with mouse anti-
SR-BI antibody (which also inhibits binding of ligands to human CLA-1) [72]. Likewise, CCL2 
production in SAA-stimulated synovial fibroblasts from osteoarthritis patients was 
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significantly, but not completely, inhibited by treatment of cells with the TLR4 inhibitor 
TAK242, whereas this production also (not significantly) diminished upon treatment of cells 
with anti-RAGE antibody. CCL2 production in SAA-stimulated primary chondrocytes from the 
same patients was also reduced after preincubation of cells with TAK242 (significant) or with 
RAGE or anti-SR-BI antibody (not significant). Treatment of synoviocytes or chondrocytes 
with the irreversible CD36 inhibitor SSO or with the FPR2 agonist lipoxin A4 did not alter the 
CCL2-inducing capacity of SAA [29]. 
 Several reports described CXCL8 production in SAA-stimulated cells 24 h post 
induction. Neutrophils, monocytes and, to a lesser extent, endothelial cells were studied. 
Monocytes produced greater amounts of chemokine than neutrophils [51, 76, 77], as 
already shown by other investigators in response to other stimuli [78-80]. Moreover, 17-125 
µg/ml SAA was required to significantly induce CXCL8 in neutrophils [50, 51, 76, 77, 81, 82], 
whereas, in monocytes, 10-100 ng/ml of SAA already induced about 10 ng/ml of CXCL8 3 h 
after stimulation [76, 83]. In a 24 h period, monocytes and macrophages produced 10-50 
ng/ml of CXCL8 in response to 10-25 ng/ml SAA [53]. Endothelial cells more potently 
produced CXCL8 than CCL2, since treatment with only 0.5-1.25 µg/ml SAA during 8 or 24 h 
significantly induced 10-20 ng/ml of CXCL8 [61, 62, 75], whereas generally higher 
concentrations of SAA were necessary to induce a substantial amount of CCL2 (vide supra). 
Maximal production of CXCL8 was reached 20-24 h after SAA stimulation of monocytes (50-
400 ng/ml) [53, 76, 77, 83], neutrophils (10-45 ng/ml) [50, 77, 84] or immature dendritic cells 
(30 ng/ml) [83]. SAA induced, from 3-4 h post stimulation onwards, significant amounts of 
CXCL8 in monocytes (about 10 ng/ml) [76, 83], neutrophils (about 1 ng/ml) [82] and 
immature dendritic cells (about 15 ng/ml) [83]. In our hands, SAA did not induce significant 
amounts of CXCL8 in neutrophils [76]. 
Furthermore, it has to be noted that Song and co-workers [53] explored cytokine 
production in SAA-stimulated lymphocytes. They found that T lymphocytes produced a very 
low, but significant amount of CXCL8 (50 pg/ml), but not of IL-1β, IL-6, GM-CSF, IL-10, TNF, 
CCL2 or CCL3, after stimulation with a very low concentration of SAA (25 ng/ml). A ten-fold 
higher dose of SAA induced less but still significant amounts of CXCL8 (about 20 pg/ml). 
Similar to the induction of some cytokines, several receptors have been reported to 
mediate CXCL8 induction in SAA-stimulated cells: TLR2, TLR4, FPR2, CLA-1 and CD36 (Table 
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3). Receptor transfected cell lines were often used to show receptor-specific production of 
CXCL8 upon stimulation with SAA [28, 63, 85, 86]. In our hands, SAA-induced production of 
CXCL8 was mediated through TLR2, as the production of CXCL8 in monocytes diminished 
significantly (62% inhibition) upon treatment of cells with anti-TLR2 antibody [76]. In 
contrast, the FPR2 antagonist WRW4 did not influence CXCL8 induction, nor could we detect 
any significant CXCL8 production in human FPR2-transfected human embryonic kidney 293 
(HEK293) cells stimulated with SAA, indicating that not FPR2, but TLR2 mediates CXCL8 
induction in SAA-stimulated cells. This is not in agreement with the finding that 
preincubating neutrophils with pertussis toxin, which blocks signaling through Gαi proteins, 
strongly reduced (about 80% inhibition) SAA-induced CXCL8 production [82]. Further, human 
FPR2-transfected Chinese hamster ovary (CHO) cells and human FPR2-transfected A549 lung 
epithelial cells were able to produce CXCL8 upon stimulation with SAA [28, 86]. In contrast, 
treatment of synovial fibroblasts and primary chondrocytes from osteoarthritis patients with 
lipoxin A4 did not inhibit CXCL8 induction when these cells were stimulated with SAA [29]. 
Treating these cells with anti-SR-BI or anti-RAGE antibody or with the CD36 inhibitor SSO did 
not alter CXCL8 production either. On the other hand, just as described for IL-6, CCL2 and 
CXCL1 production, a significant inhibition of SAA-induced CXCL8 production was obtained 
when the synoviocytes or chondrocytes were preincubated with the TLR4 inhibitor TAK242. 
CD36 was also stipulated as a receptor mediating SAA-induced CXCL8 production in CD36-
transfected HEK293 cells [85], but this finding is controversial [29]. Another putative 
receptor mediating SAA-induced CXCL8 production is CLA-1. Treatment of endothelial cells 
with anti-SR-BI antibody potently reduced CXCL8 production after stimulation with SAA. The 
production of this chemokine in two out of three SAA-stimulated cultures of synovial 
fibroblasts from RA patients was also diminished using this antibody [62]. This last finding 
illustrates once more that probably, depending on the cell type, different receptors are 
involved in SAA-induced cytokine production and that there might even be an interplay 
between receptors of different classes. 
3.1.3. Influence of HDL on the cytokine-like properties of SAA 
Researchers studying the cytokine-inducing properties of SAA mostly used a recombinant 
SAA form under serum-free conditions. However, in the blood circulation, SAA is preferably 
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bound to HDL. Therefore, a HDL-conjugated SAA form was used in some studies to 
investigate whether this HDL-binding could influence its cytokine- and chemokine-inducing 
capacity. Baranova et al. [85] showed that binding of SAA to HDL reduced CXCL8 induction in 
CD36-transfected HEK293 cells up to 70% after 20 h of stimulation. This inhibition 
diminished as the SAA/HDL molar ratio increased (SAA from 10 to 1000 µg/ml, bound to 2 
mg/ml HDL, corresponding to a SAA/HDL molar ratio of 1:20 to 1:0.2), like is the case during 
the acute phase response. Thus, during such acute phase response, SAA (partly) bound to 
HDL should still be able to induce a substantial amount of CXCL8. In our study, we 
deliberately used a relatively low SAA/HDL molar ratio (1 µg/ml SAA bound to 2 mg/ml HDL) 
to induce CXCL8 in monocytes. SAA at 1 µg/ml clearly induced CXCL8 (about 450 ng/ml) in 
monocytes 24 h post stimulation. In line with the results of Baranova et al. (2010), CXCL8 
induction was completely (96%) inhibited at this low SAA/HDL molar ratio [76]. Furthermore, 
Furlaneto and Campa [50] also demonstrated an inhibition of the induction of IL-1β, TNF-α 
and CXCL8 in neutrophils treated with HDL-SAA. Stimulation of cells with 100 µg/ml of SAA 
strongly induced these cytokines, whereas their production was completely blocked when 
cells were stimulated with HDL (containing SAA) from patients with an infection and thus 
undergoing an acute phase response. 
 On the other hand, Patel et al. [87] reported that purified HDL, containing 30 µg/ml 
SAA, induced (6 h) practically the same amount of IL-1β in THP-1 cells as pure synthetic HDL-
free SAA1α. When another 30 µg/ml of SAA was added to the HDL-SAA preparation (without 
preincubation), even more IL-1β was induced. Moreover, Lee et al. [71] showed that 
induction of CCL2 in monocytes (24 h) was not affected by HDL-conjugated SAA. However, in 
the latter study a relatively high SAA/HDL molar ratio was used, which was probably the 
reason for the lack of inhibition. 
3.2. Chemokine induction by endogenous (cytokines) and exogenous (TLR ligands) 
inflammatory mediators 
The previously mentioned data in this overview illustrate that the acute phase protein SAA 
induces production of higher amounts of chemokines than of cytokines. Moreover, 
compared to the amount of SAA needed for induction of cytokines, lower SAA 
concentrations are required to induce chemokines. Other well-known and potent chemokine 
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inducers are the TLR4 agonist LPS and the SAA-inducing cytokine IL-1β (Table 4). In fact, SAA 
is as potent as LPS and IL-1β in terms of maximal amounts of chemokines produced. 
Depending on the cell type, SAA, LPS or IL-1β induced respectively (24 h) 2-400 ng/ml [53, 
61, 74, 76, 83], 3-400 ng/ml [83, 88-90] or 7-400 ng/ml [83, 89, 91] of CXCL8, CCL2 and CCL3. 
Furthermore, the concentration of SAA required to induce chemokines is comparable with 
that of LPS. SAA induces chemokines already at concentrations in the ng/ml range, i.e. 10 
ng/ml of SAA being sufficient to significantly induce CXCL8 (8 ng/ml) in monocytes 3 h post 
stimulation [83]. IL-1β is even able to induce significant amounts of chemokine at still lower 
concentrations (≤ 1 ng/ml) than SAA and LPS [83, 89-94]. Gouwy et al. [83] showed that IL-1β 
at 1 ng/ml induced already 5-10 ng/ml CXCL8 and CCL3 in immature dendritic cells after 4 h. 
The other two SAA-inducing cytokines, TNF-α and IL-6, are also able to induce 
chemokines (Table 4). Cells treated with TNF-α during maximally 24 h produce 5-600 ng/ml 
chemokine [91, 95, 96], which is comparable with chemokine production in SAA-stimulated 
cells. However, just as for IL-1β, lower concentrations of TNF-α (1-20 ng/ml) are generally 
needed to induce chemokines [91, 92, 94, 96-99]. On the other hand, a limited number of 
reports is available on chemokine induction by IL-6. IL-6 in general is a less potent inducer of 
the inflammatory chemokines CXCL8, CCL2 and CCL3 than SAA, IL-1β, TNF-α and LPS. 
 Not all cytokines induce the same type of chemokines. For instance, the class II 
cytokine family member IFN-γ is generally a poor CXCL8, CCL2 and CCL3 inducer (Table 4). 
Highly inducible chemokines by IFN-γ are the angiostatic CXCR3 ligands CXCL9, CXCL10 and 
CXCL11 [98, 100, 101]. Two to 20 ng/ml of IFN-γ is required to induce up to 2 µg/ml CXCL10 
in endothelial cells after 72 h stimulation [98, 100]. In one study, IFN-γ (5 ng/ml) was 
reported to induce 15 ng/ml CCL3 in monocytes [102], but in other studies, IFN-γ (2-2000 
ng/ml) did not induce chemokines (except for CXCR3 ligands) in monocytes [80, 89, 98, 103, 
104]. On the contrary, it was found that this cytokine inhibited CXCL8 production, since low 
concentrations of IFN-γ (5-10 ng/ml) reduced CXCL8 expression in LPS- or TNF-α-stimulated 
neutrophils and fibroblasts [103, 105]. The same inhibitory effect of IFN-γ on CXCL6 
production was seen in fibroblasts treated with IL-1β, TNF-α, LPS or double-stranded RNA 
(dsRNA) [94]. 
Exogenous dsRNA, which is mostly mimicked by synthetic 
polyriboinosinic:polyribocytidylic acid (polyrI:rC) in induction experiments, is also a 
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chemokine inducer via binding to a TLR, namely to TLR3 (Table 4). About 10 µg/ml of 
polyrI:rC is generally needed to induce chemokines, which is modestly higher than the 
amount of SAA required for chemokine induction in monocytes and endothelial cells. 
However, polyrI:rC- and SAA-stimulated cells produce comparable amounts of the 
inflammatory chemokines CXCL8 and CCL2, i.e. 10-175 ng/ml being produced after 24 to 72 
h stimulation with polyrI:rC [89, 92-94, 101, 104]. 
Taken together, cytokines which induce the chemokine-inducing SAA (IL-1β, TNF-α, 
IL-6) are also able to directly induce chemokines. Furthermore, concerning the concentration 
required to induce chemokines, we can state the following: dsRNA ≥ SAA = LPS > IL-1β = TNF-
α, reflecting their levels during infection. In contrast to the different amounts of inducers 
needed for chemokine induction, the maximal production levels of chemokines is 
comparable between these SAA inducers. Both endogenous (i.e. IL-1β, TNF-α, IL-6, SAA) and 
exogenous (i.e. LPS, dsRNA) inflammatory mediators thus create a massive chemokine 
network, which amplifies the migratory potency of leukocytes during the inflammatory 
response (Fig. 1). 
3.3. SAA as a chemoattractant 
3.3.1. Human SAA target cells for chemotaxis 
In comparison to the cytokine-inducing capacity of SAA, its chemotactic potency is relatively 
poorly studied. Cells responsive to SAA in chemotaxis assays are shown in Table 5. In Boyden 
chamber chemotaxis assays, the chemotactic potency of a chemoattractant can be 
expressed as a chemotactic index (CI), calculated by dividing the number of migrated cells to 
the chemoattractant by the number of migrated cells to the negative buffer control. 
Although its CI is mostly low, SAA at 10 µg/ml has been reported to stimulate the directed 
migration of human monocytes, neutrophils, immature dendritic cells, T cells, mast cells, 
endothelial cells, smooth muscle cells and synovial fibroblasts (Table 5). However, 
monocytes and immature dendritic cells are more sensitive to SAA as a chemoattractant, 
since already 12.5 and 100 ng/ml of SAA, respectively, provoked significant chemotaxis [71, 
83]. In contrast, neutrophils significantly migrated towards SAA from a concentration of 1 
µg/ml onwards [76]. The chemotactic potency of SAA on synovial fibroblasts from patients 
with RA was assessed by a wound repair assay [72]. After 24-48 h, clearly more cells 
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repopulated an artificial wound made in a confluent cell layer upon stimulation of the cells 
with SAA than when cells were stimulated with vehicle (i.e. 1% DMSO). Moreover, SAA was 
shown to induce ruffling of the membrane of synovial fibroblasts and to mediate its 
chemotactic effect by active remodeling of the actin cytoskeleton, creating lamellopodia and 
philopodia. 
Since SAA is a very weak chemoattractant, the question may rise whether the 
migration of cells towards this acute phase protein is caused by a chemokinetic effect, i.e. a 
random, undirected movement of the cells. To test this possibility, SAA was added together 
with the cells to the upper instead of the lower compartment of a chemotaxis chamber. Xu 
et al. [106] and Olsson et al. [107] demonstrated that SAA did not induce chemokinesis in T 
cells and mast cells, respectively. On the contrary, on neutrophils [108] and monocytes [83] 
a mild chemokinetic effect was noticed upon stimulation with SAA, but the chemokinetic 
effect was weaker than its chemotactic effect. 
SAA has also been tested as a chemoattractant in vivo. Subcutaneous (SC) injection of 
mice with SAA (10 or 50 µg daily) provoked a clear recruitment of neutrophils and 
monocytes towards the injection site after 72 h [87, 108]. The same effect was seen with T 
cells 24 h after a simple SC injection of 10 µg SAA [106]. SC injection of mice with 120 µg/kg 
(about 3 µg/mouse) SAA once a day caused a significant neutrophilia after 48 h, with a 
maximal neutrophilia after 5 days [109]. Furthermore, intranasal administration of 2 µg SAA 
to mice weekly for five weeks resulted in recruitment of significantly higher numbers of 
neutrophils into the lungs and bronchoalveolar lavages (BAL) than in saline-treated mice 
[110]. Moreover, we recently found that intraperitoneal (IP) injection of only 1 µg SAA in 
mice also caused a rapid and significant influx of neutrophils into the peritoneal cavity 2 h 
post injection [76]. 
3.3.2. The role of SAA-induced chemokines and cytokines in the chemotactic response 
to SAA 
In contrast to the chemotactic activity of human CXCL8 or mouse CXCL6, which is the murine 
counterpart of CXCL8, SAA proved to be a more potent neutrophil chemoattractant when 
injected IP into mice than when it was applied in in vitro Boyden chemotaxis assays. Indeed, 
a 5000-fold higher concentration of SAA was needed to acquire the same in vitro 
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chemotactic effect as CXCL8, whereas only a ten-fold higher concentration of SAA was 
required to recruit even more neutrophils to the peritoneal cavity than mouse CXCL6 [76]. In 
fact, we demonstrated that this phenomenon was due to a rapid (within 2-3 h) induction of 
CXCL8 (or equivalent mouse CXCL6) in monocytes, which subsequently synergized with SAA 
to recruit an even greater number of neutrophils than the sum of neutrophil migration 
towards SAA and the induced chemokine tested separately. Lymphocytes and monocyte-
derived macrophages are the main leukocyte cell populations in the peritoneal cavity. Since 
monocytes and macrophages are very good producers of chemokines when stimulated with 
SAA [53, 76, 83] and since lymphocytes are poor chemokine producers [53], we can assume 
that the former cells, possibly together with mesothelial cells delineating the peritoneal 
cavity, are contributing to the induction of chemokines. In line with these results, the 
recruitment of monocytes, neutrophils and T cells to the injection site 4-72 h after SC 
administration of SAA [87, 106, 108] is probably also enforced by the local induction of 
cytokines and chemokines in fibroblasts, macrophages and endothelial cells (vide supra), 
which mediate the accumulation of supplementary leukocytes at the injection site. Indeed, 
He et al. [109] showed that the neutrophilia in SAA-treated (SC) mice was caused by 
induction of G-CSF, which mobilizes neutrophils from the bone marrow to the blood. 
The induction of chemokines by SAA did not only influence its in vivo chemotactic 
potency, it was also found to affect in vitro cell migration to SAA. Indeed, in a previous study 
we pointed out that within the Boyden chamber the migration of monocytes and immature 
dendritic cells towards SAA was mediated by rapid (within 2-3 h) induction of CCL3 and 
CXCL8, which subsequently synergized with each other and possibly also with SAA to 
chemoattract even more cells than when only the effect of SAA would be taken into account 
[83]. This was evidenced by a significantly higher concentration of CCL3 and CXCL8 produced 
by the migrated cells in the lower wells of the chemotaxis assay upon stimulation of cells 
with SAA, compared to the concentration of chemokine in the upper wells. In addition, 
treatment of cells with antagonists of the CCL3 receptors CCR1 and CCR5 or with antibodies 
against CCL3 and/or CXCL8 significantly inhibited the chemotactic response of monocytes 
towards SAA [83]. 
In contrast to monocytes, neutrophils stimulated with SAA were not able to express 
CXCL8 or CCL3 within the duration of the chemotaxis assay [76]. Hence, the weak 
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chemotactic activity of SAA for neutrophils in the Boyden microchamber assay (duration of 
45 min) is a direct effect of SAA. This is in agreement with the study of Connolly and co-
workers [72], in which they found that the trans-endothelial migration of neutrophils (24 h 
assay duration) towards 10 or 50 µg/ml SAA was (majorly) elicited by induction of CXCL8 in 
the endothelial cells. In addition, Ather et al. [111] proved that, compared to saline-treated 
mice, the higher amount of neutrophils recruited into BAL fluid of mice treated with 10 µg 
SAA during 4 h via oropharyngeal aspiration was the result of the induction of IL-1β. Indeed, 
BAL fluids of SAA-treated mice contained significantly higher amounts of IL-1β after 4 h 
stimulation than BAL fluids of saline-treated mice and the IL-1R antagonist Anakinra 
significantly reduced the number of neutrophils in BAL fluid of mice treated with SAA for 24 
h. Probably, an SAA-IL-1β/IL-6-IL-17A-CXCL1 induction cascade is responsible for the influx of 
neutrophils (migrating to CXCL1) into the BAL fluid of SAA-treated mice. Evidence for this 
statement was given by the fact that the expression of IL-1β, IL-6 (both inducers of IL-17A) 
and IL-17A in BAL fluid after intranasal administration of SAA was significantly higher than in 
BAL fluid of saline-treated mice [110]. Moreover, treatment of mice with anti-IL-17 antibody 
prior to treatment with SAA decreased neutrophil recruitment to lungs and BAL fluid and 
significantly reduced the expression of CXCL1, but not of CXCL2 [110]. 
3.3.3. Influence of HDL on the chemotactic properties of SAA 
Although Lee et al. [71] stated that HDL did not have any effect on the chemotactic activity 
of SAA on monocytes, four other papers reported the contrary. Badolato et al. [108] and Xu 
et al. [106] demonstrated that HDL dose-dependently inhibited the migration of monocytes, 
neutrophils and T cells towards SAA. In contrast to the SAA-induced production of cytokines, 
which was not affected by HDL at high SAA/HDL molar ratios, the chemotactic activity of 
HDL-conjugated SAA was already greatly impaired at relatively high SAA/HDL molar ratios, 
whereas the effect of HDL on the chemotactic activity towards other chemoattractants was 
minimal [106, 108]. Furthermore, conjugation of HDL (1 mg/ml) with SAA (10 µg/ml), almost 
completely inhibited chemotaxis of FPR2-transfected HEK293 cells to SAA [112]. Moreover, it 
was evidenced by Patel et al. [87] that HDL also markedly reduced the in vivo chemotactic 
properties of SAA. After SC injection of HDL-conjugated SAA or HDL co-injected with 30 µg 
SAA, these authors found that there was macroscopically no swelling or signs of 
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inflammation at the injection site, which was indeed the case when only SAA was injected. In 
addition, clearly less monocytes and neutrophils were infiltrated at the injection site in the 
presence of HDL. Taken together, HDL inhibits SAA-mediated chemotactic responses in a 
more pronounced way than the SAA-mediated induction of cytokines (vide supra). 
3.3.4. Receptors mediating the SAA-induced chemotaxis 
Until now, only FPR2 has been reported to mediate the chemotactic activity of SAA [112, 
113]. This GPCR is also a low binding affinity receptor for the bacterial N-formyl-methionyl-
leucyl-phenylalanine (fMLF). Besides fMLF, FPR2 also interacts with other chemotactic 
pathogen-associated molecular patterns (PAMPs) and with chemotactic damage-associated 
molecular patterns (DAMPs; e.g. SAA) [114]. In the early studies reporting the chemotactic 
activity of SAA, the use of a GPCR on monocytes, T cells and mast cells was already 
evidenced [106, 107, 115]. In 1999, the group of Su et al. [112] was able to identify human 
FPR2 as the receptor responsible for SAA-mediated chemotaxis. These researchers 
evidenced this by multiple findings. Firstly, SAA induced migration of human FPR2-
transfected HEK293 cells from 125 ng/ml onwards to reach a maximal CI at 12.5 µg/ml, 
whereas fMLF at these concentrations was not able to provoke a chemotactic response. 
Secondly, SAA was able to induce a rise in intracellular Ca2+ concentration in the same cells, 
which is a typical chemoattractant-related intracellular signal. This Ca2+ response was 
inhibited by pertussis toxin, suggesting that it was mediated by binding to a GPCR. Thirdly, 
SAA binding experiments showed that SAA specifically bound to human FPR2-transfected 
HEK293 cells. fMLF competed only at high concentrations with SAA for binding to the cells, 
again suggesting that binding of SAA to the cells was FPR2-, but not FPR1-mediated. 
In line with the findings of the group of Su et al., we found that FPR2 also mediated 
the synergy between SAA and CXCL8 to chemoattract neutrophils [76], confirming that FPR2 
is the receptor mediating the SAA-induced chemotactic activity. This was also supported by 
the finding of Chen et al. [116] that SAA-stimulated human FPR2-transfected rat basophilic 
leukemia RBL-2H3 cells showed a rise in intracellular Ca2+ concentration and exhibited a 
chemotactic response towards the acute phase protein. In fact, these authors demonstrated 
that the SAA isoforms have a different mode of action by preferably binding specific 
receptors, since human SAA1α and SAA2β preferably bound to mouse FPR2, but not to TLR2 
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or TLR4, to provoke a chemotactic response of the cells. With regard to the synergy between 
SAA and SAA-induced chemokines in the chemotactic response, we have shown that both 
FPR2 and the receptors of the induced chemokines are involved [76]. 
SAA equally signals through FPR2 to chemoattract mouse cells. HEK293 cells 
transfected with mouse FPR2, like mouse neutrophils, were weakly chemoattracted by SAA 
at a concentration of 12.5-25 µg/ml onwards. Moreover, a rise in intracellular Ca2+ 
concentration in the mouse FPR2-transfected HEK293 cells was also observed [117]. 
3. Remarks and conclusions 
The SAA family of acute phase proteins consists mainly of the A-SAA proteins SAA1 and SAA2 
and the C-SAA protein SAA4. Like inflammatory chemokines, A-SAA has inflammatory 
properties at higher concentrations (100 ng/ml), but its serum levels can rise up to 1000-fold 
during inflammation. In fact, several pro- and anti-inflammatory functions have been 
ascribed to this highly conserved acute phase protein. SAA was found to be chemotactic for 
neutrophils, monocytes, T cells and mast cells, but the mode of action of its chemotactic 
activity was until recently poorly studied. We found that the monocyte chemotactic activity 
of SAA1α is due to rapid induction of the inflammatory chemokines CXCL8 and CCL3, which 
subsequently cooperate with each other to enhance monocyte migration. Moreover, we 
showed that the SAA-induced CXCL8 in mononuclear cells can synergize with SAA1α to 
attract neutrophils in vitro and in vivo (Fig. 2). Our observations are in line with the work of 
Connolly and co-workers [72] who demonstrated that CXCL8, induced in endothelial cells by 
SAA, is involved in trans-endothelial migration of neutrophils towards SAA. SAA-mediated 
induction of IL-1β and IL-6, leading to further induction of chemokines, was also found to be 
responsible for the higher neutrophil counts in BAL fluids from mice treated with SAA [110, 
111]. Hence, besides having a direct chemotactic effect, SAA also acts as a leukocyte 
chemoattractant in an indirect way, via induction of chemokines and cytokines. Indeed, a 
variety of primary mediators (e.g. SAA) is produced simultaneously at an inflammatory site 
and an array of secondary effector molecules (including cytokines and chemokines) is 
secreted by the stimulated cells. These effector molecules can act in concert (e.g. SAA with 
chemokines) to attract leukocytes to the inflammatory site. 
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Other functions described for SAA may also be exerted in an indirect way. SAA 
induces autocrine and paracrine cytokine and chemokine production in a variety of cell types 
(Tables 2 and 3). These cytokines and chemokines are communication molecules which are 
eventually responsible for very diverse effects and which can mediate the outcome of SAA 
functions via their fine-tuned network [118]. Actually, it was demonstrated that monocyte 
adhesion in response to SAA was mediated by induction of CCL2 [72]. Investigating the 
involvement of cytokine and/or chemokine induction in the various described effects 
mediated by SAA will thus be of great interest in future studies. 
Since the commercially available SAA forms are recombinant proteins expressed in E. 
coli, the question rises whether contamination with LPS may be responsible for some of its 
biological effects. In the past, several studies included the Limulus amebocyte lysate assay or 
other tests to determine the role of LPS in the observed biological effects of recombinant 
SAA preparations [71, 73, 82, 109, 112, 119]. In none of these studies, low LPS 
contamination (< 100 pg/ml) was found to influence the biological properties of SAA. Just 
like observed by He and colleagues [82], we showed that LPS at concentrations equal to 
those present in the recombinant SAA preparation did not result in the production of 
chemokines [83]. Similarly, antibodies against TLR4 did not reduce the SAA-mediated G-CSF 
production in murine macrophages, nor did macrophages of TLR4-deficient mice, stimulated 
with recombinant SAA, produce less G-CSF than macrophages of wild type mice [109]. 
Several other cytokines were equally well produced by SAA-stimulated macrophages from 
TLR4-deficient mice, indicating that the TLR4 ligand LPS is not responsible for this biological 
effect [116]. 
 It has been reported that SAA elicits its functions via interaction with various 
receptors. Despite numerous experimental efforts to identify the receptor(s) mediating the 
SAA-induced cytokine and chemokine production, there is no consensus about a single 
receptor being responsible for this SAA-mediated biological activity. The toll-like receptors 
TLR2 and TLR4 and the formyl-peptide receptor FPR2, which is also the receptor mediating 
the chemotactic response of leukocytes towards SAA, were all shown to mediate cytokine 
and chemokine induction [28, 29, 52, 54, 55, 59-61, 69, 71, 73, 74, 76, 82, 86]. Other 
receptors reported to be used by SAA to induce cytokines and chemokines are the scavenger 
receptors CD36 and CLA-1 (abbreviation for CD36 and LIMPII analogous-1). CD36 is a 
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membrane protein belonging to the class B scavenger receptor family. This receptor is 
present on various cell types and recognizes a variety of ligands. Since CD36 exerts its 
functions by interacting with other receptors, including TLRs, one can assume that this 
scavenger receptor functions as a co-receptor for TLRs, just like CD14 is for TLR4, and that a 
combination of TLR2 and CD36 is thus needed to induce cytokines and chemokines [120]. 
CLA-1 is the human homologue of murine scavenger receptor class B type I (SR-BI) and is 
genetically related to CD36 and rat LIMPII, another member of the scavenger receptor class 
B family [121]. Nevertheless, the use of CD36 and CLA-1 by SAA to induce cytokines and 
chemokines is poorly studied and needs more investigation. We found that SAA induced 
CXCL8 in monocytes through interaction with TLR2, but not through binding to FPR2. 
Therefore, we postulate that SAA predominantly activates TLR2 for cytokine and chemokine 
induction, whereas FPR2 is used for SAA-mediated cell chemotaxis. FPR2 belongs to the class 
of GPCRs, which include the classical chemokine receptors. Such receptors interact with 
chemotactic pathogen-associated (e.g. FPR1 for fMLF) and damage-associated (e.g. FPR2 for 
SAA) molecular patterns (PAMPs and DAMPs), which are structurally very diverse [114]. 
Peptides from Listeria function as early chemotactic PAMPs for neutrophils through binding 
to FPR2. Just like SAA, these bacterial peptides also bind to TLR2 on hepatocytes and 
leukocytes, thereby inducing chemokine ligands for CXCR2, which provoke a late wave of 
neutrophil influx into the infected liver [122]. Another finding supporting the use of TLR2 for 
SAA-mediated cytokine and chemokine induction is the fact that SAA upregulates the 
expression of TLR2 on endothelial cells, which may amplify its cytokine and chemokine 
inducing capacity [61]. Stimulation of TLR2 or TLR4 also increases the expression levels of 
FPR2 in mice, facilitating the SAA-mediated leukocyte chemotactic activity [123, 124]. 
Taken together, when TLR2 or TLR4 on leukocytes interacts with PAMPs from gram-
positive (peptidoglycan) or gram-negative (LPS) bacteria, respectively, these cells start 
producing cytokines. The cytokines greatly augment the synthesis of acute phase proteins 
(i.e. SAA) in the liver. In turn, SAA functions as a weak chemotactic DAMP for leukocytes, 
acting via interaction with FPR2, and induces chemokines through binding to TLR2. SAA-
induced chemokines cooperate and act synergistically with SAA itself to attract leukocytes. 
Simultaneously, these chemokines function in a signal relay, propagating the chemotactic 
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message to a wider extent. Subsequently, this highly coordinated chemotactic cascade leads 
to an optimization of the recruitment of leukocytes to sites of inflammation. 
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Figure legends 
Figure 1. The cytokine-SAA-chemokine network 
Exogenous inflammatory mediators, such as LPS, stimulate macrophages to produce TNF-α 
and IL-1β, which in turn induce the production of the acute phase protein SAA in the liver. At 
the same time, TNF-α and IL-1β stimulate the production of IL-6 in endothelial cells and 
fibroblasts. IL-6 on its own or in synergy with TNF-α and/or IL-1β (bold black arrow) also 
triggers the production of SAA in the liver. Endogenous TNF-α, IL-1β and SAA induce CXC and 
CC chemokines in various cell types [e.g. macrophages, dendritic cells (DC), monocytes, 
endothelial cells, fibroblasts]. The induced chemokines subsequently stimulate the migration 
of leukocytes (e.g. monocytes, neutrophils, DC) to the site of inflammation (blue arrows). 
Furthermore, CXC and CC chemokines can synergize (bold blue arrows) with each other, but 
also with SAA, to enhance leukocyte migration to inflammatory foci. 
Figure 2. Mechanism of chemotactic activity of SAA1α on monocytes and neutrophils 
SAA1α chemoattracts monocytes and neutrophils through binding to FPR2 (red arrows). At 
the same time, this acute phase protein activates TLR2 on monocytes, leading to induction of 
chemokines in monocytes, such as CCL3 and CXCL8 (black arrows). CCL3 and CXCL8 cooperate 
to enhance monocyte recruitment (large green arrows) via binding to their corresponding 
receptors, which are CCR1/5 (orange arrow) and CXCR1/2 (purple arrow), respectively. On 
neutrophils, SAA1α and CXCL8 synergize by binding to FPR2 and CXCR2, respectively (large 
green arrows). 
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Table 1. In vitro induction of SAA in hepatocytes 
Cells Inducer 
SAAa A-SAAb SAA4 (C-SAA) 
References 
mRNA protein mRNA protein mRNA protein 
Primary human 
hepatocytes 
dex 
 
- 
    
[34] 
mu IL-1α + dex / IL-6 ± dex / mu IL-1α + IL-6 + dex 
 
+ 
    
[34, 36] 
Hep3B 
hepatoma cells 
none / dex 
  
- 
 
+ 
 
[33] 
MoCM ± dex 
  
+ 
 
+ 
 
[33] 
IL-1α / IL-1β / IL-6 / TNF-α / dex - - 
    
[13, 14, 23] 
IL-1β / IL-6 / IL-1β + IL-6 +      [15] 
IL-1α + IL-6 ± dex / IL-1β + IL-6 / IL-6 + TNF-α + + 
    
[14, 23] 
HepG2 
hepatoma cells 
none / dex 
  
- 
 
+ 
 
[33] 
MoCM ± dex 
  
+ 
 
+ 
 
[33] 
IL-1β ± dex 
 
+ + 
   
[17, 20] 
IL-6 / dex / IL6 + dex  -     [20] 
IL-1 / IL-6 / IL-1β ± IL-6 / IL-1 + IL-6 ± dex / TNF-α ± IL-6 
 
+ + 
   
[16, 19, 20] 
IL-1α ± pred / IL-1β ± pred / IL-6 ± pred / TNF-α / pred /    
IL-6 + TNF-α + pred 
 -     [22] 
IL-6 / TNF-α / IL-6 + TNF-α 
  
+ 
   
[18] 
IL-1α + IL-6 ± pred / IL-1β + IL-6 ± pred 
 
+ 
    
[22] 
HuH7 hepatoma 
cells 
none 
  
+ 
 
+ 
 
[30, 125] 
none / dex 
  
- 
 
+ 
 
[33] 
MoCM ± dex 
  
+ 
 
+ 
 
[33] 
IL-6 / TNF-α 
 
- 
    
[25] 
IL-1β ± IL-6 / IL-6 + TNF-α 
 
+ 
    
[25] 
PLC/PRF/5 
hepatoma cells 
none / dex 
  
- - + 
 
[21, 33, 35] 
MoCM ± dex 
  
+ 
 
+ 
 
[33] 
IL-6 
 
+ + 
   
[21, 23] 
IL-1β ± IL-6 / IL-1β + dex ± IL-6 
  
+ 
   
[21] 
IL-1β + IL-6 + dex 
  
+ + 
  
[35] 
Abbreviations: dex: dexamethasone; MoCM: monocyte conditioned medium; mu: murine; pred: prednisolone 
a
 Not specified which SAA type produced 
b A-SAA expression without discrimination between SAA1 and SAA2 
The presence or absence of SAA, A-SAA (SAA1 and SAA2), and/or SAA4 (C-SAA) mRNA and/or protein in hepatocytes or hepatoma cell lines is indicated by + or -, respectively 
Table 2. SAA-mediated cytokine production by human cell types. 
Cytokine 
family 
Cytokine 
induced 
Producer cellsa 
SAA 
receptor 
References 
IL-1 IL-1β macrophages, keratinocytes TLR2+TLR4 [54, 58] 
monocytes, macrophages, 
neutrophils, THP-1 cells, U937 
cells, HMC-1 mast cells; 
synoviocytes (mRNA) 
ND
b [50, 51, 53, 55-58, 
87] 
IL-1RA monocytes (mRNA), THP-1 cells ND [87, 126] 
IL-33 THP-1 cells TLR2+FPR2 [59] 
Class I cytokine IL-6 endothelial cells, fibroblasts TLR2 [60, 61] 
synovial fibroblasts, 
chondrocytes 
TLR4 [29] 
endothelial cells, synovial 
fibroblasts 
CLA-1 [62] 
monocytes, macrophages, 
endothelial cells, U937 cells, 
synovial fibroblasts, 
synoviocytes 
ND 
[42, 44, 53, 55, 75, 
127] 
IL-23 monocytes, U937 cells, 
synoviocytes 
ND [55, 56, 70] 
GM-CSF endothelial cells TLR2 [61] 
hu FPR2-transfected A549 cells FPR2 [28] 
monocytes, macrophages ND [53] 
G-CSF monocytes ND [109] 
M-CSF HepG2 cells FPR2 [55] 
Class II 
cytokine 
IL-10 macrophages TLR2 [69] 
U937 cells FPR2 [55] 
monocytes, macrophages, 
synoviocytes 
ND [53, 68, 126, 127] 
TNF TNF-α macrophages TLR2 [69] 
monocytes, macrophages, 
neutrophils, U937 cells, HMC-1 
mast cells, synoviocytes 
ND 
[50-52, 55, 58, 66-
68, 82] 
IL-17 IL-17A hu FPR2-transfected A549 cells FPR2 [110] 
a 
Unless indicated, cytokine protein was measured 
b
 ND: not determined 
 
 
Table 3. SAA-mediated chemokine production by human cell types. 
Chemokine 
induced 
Producer cellsa 
SAA 
receptor 
References 
CCL1 
U937 cells 
THP-1 cells ND
b [55] 
[128] 
CCL2 
monocytes 
endothelial cells 
HepG2 cells 
hu FPR2-transfected A549 cells 
FPR2 
[71] 
[73, 74] 
[55] 
[28] 
synovial fibroblasts, chondrocytes TLR4 [29] 
synoviocytes CLA-1 [72] 
monocytes, macrophages 
endothelial cells 
synoviocytes 
THP-1 cells (mRNA) 
ND 
[53] 
[72, 75] 
[127] 
[128] 
CCL3 
monocytes 
macrophages 
dendritic cells 
THP-1 cells 
ND 
[53, 83] 
[53] 
[83] 
[128] 
CCL4 
synoviocytes 
THP-1 cells 
ND 
[127] 
[128] 
CCL5 endothelial cells ND [61] 
CCL17 
monocytes (mRNA) 
U937 cells 
ND 
[126] 
[55] 
CCL20 synoviocytes ND [127] 
CXCL1/2/3 
synovial fibroblasts, chondrocytes TLR4 [29] 
synoviocytes 
endothelial cells 
ND 
[127] 
[61] 
CXCL8 
neutrophils 
hu FPR2-transfected CHO cells 
hu FPR2-transfected A549 cells 
FPR2 
[82] 
[86] 
[28] 
monocytes TLR2 [76] 
synovial fibroblasts, chondrocytes TLR4 [29] 
CLA-1-transfected hela cells 
endothelial cells, synovial fibroblasts 
CLA-1 
[63] 
[62] 
CD36-transfected HEK293 cells CD36 [85] 
monocytes 
macrophages 
neutrophils 
dendritic cells 
T lymphocytes 
endothelial cells 
synovial fibroblasts 
synoviocytes 
THP-1 cells (mRNA) 
U937 cells 
caco-2 cells (mRNA), HT-29 cells 
A172 glioma cells 
ND 
[51, 53, 77, 83] 
[53] 
[50, 51, 77, 81, 84] 
[83] 
[53] 
[61, 72, 75] 
[44, 72] 
[127] 
[128] 
[55] 
[129] 
[130] 
CXCL10 endothelial cells ND [61] 
a
 Unless indicated, chemokine protein was measured 
b ND: not determined 
Table 4. Induction of chemokines by pro-inflammatory mediators. 
Inducer Receptor Cell type 
Chemokine
a 
References 
CXCL8
b CXCL10 CCL2 CCL3 
SAA 
FPR2 
neutrophils 
endothelial cells 
+ 
 
 
 
+ 
 
[82] 
[74] 
TLR2 monocytes +    [76] 
not determined 
monocytes, macrophages 
neutrophils 
dendritic cells 
endothelial cells 
+ 
- 
+ 
+ 
 
 
 
+ 
+ 
 
 
 
+ 
- 
+ 
 
[53, 83] 
[76] 
[83] 
[61] 
dsRNA TLR3 
monocytes 
macrophages 
endothelial cells 
fibroblasts 
chondrocytes 
epithelial cells 
MRC-5 cells, A549 cells 
+ 
+ 
+ 
+ 
+ 
+ 
 
+ 
 
+ 
+ 
 
 
+ 
+ 
 
+ 
 
+ 
+ 
 
 
+ 
 
 
 
 
 
[98, 104] 
[93, 131] 
[89, 92, 94, 100] 
[94, 98, 104, 132] 
[89, 94, 132] 
[133] 
[134] 
LPS TLR4 
monocytes 
macrophages 
neutrophils 
neutrophils 
dendritic cells 
endothelial cells 
fibroblasts 
chondrocytes 
+ 
+  
- 
 
+ 
+ 
+ 
+ 
- 
 
 
 
+ (mRNA) 
- 
- 
 
+ 
 
- 
 
 
+ 
 
+ 
+ 
 
- 
+ 
+ 
 
 
 
[80, 83, 90, 98, 104, 135] 
[93, 99] 
[76, 80] 
[88] 
[83, 95] 
[89, 92, 94, 100] 
[98] 
[89, 94] 
Inducer Receptor Cell type 
Chemokine
a 
References 
CXCL8
b CXCL10 CCL2 CCL3 
IL-1β 
Immunoglobulin 
family receptors 
monocytes 
monocytes 
macrophages 
neutrophils 
dendritic cells 
endothelial cells 
fibroblasts 
chondrocytes 
smooth muscle cells 
+ 
+ 
+ 
- 
+ 
+ 
+ 
+ 
+ 
 
 
 
 
 
 
 
 
 
+ 
- 
 
- 
 
+ 
+ 
+ 
 
+ 
- 
 
- 
+ 
 
 
 
 
[80, 90, 135] 
[83, 104] 
[93, 99] 
[76, 80] 
[83] 
[89, 91, 92, 94] 
[89, 94, 104, 132] 
[89, 94, 132] 
[91] 
IL-6 
Class I cytokine 
receptors 
monocytes 
endothelial cells 
U937 cells 
 
- 
- 
 
 
 
+ 
- 
+ 
 
 
- 
[136] 
[137] 
[136] 
IFN-γ 
Class II cytokine 
receptors 
monocytes 
neutrophils 
endothelial cells 
fibroblasts 
smooth muscle cells 
- 
- 
- 
- 
- 
+ 
 
+ 
+ 
 
- 
- 
- 
 
 
+ 
 
- 
 
 
[80, 89, 98, 102, 104] 
[80, 103] 
[91, 92, 94, 100, 138, 139] 
[94, 98, 104] 
[91] 
TNF-α TNF receptor family 
monocytes 
macrophages 
dendritic cells 
endothelial cells 
fibroblasts 
chondrocytes 
smooth muscle cells 
HT-29 cells, HCT-8 cells 
 
+ (mRNA) 
 
+ 
+ 
+ 
+ 
+ 
- 
 
 
 
+ 
 
 
 
 
 
 
+ 
 
 
 
+ 
- 
 
+ 
- 
 
 
- 
- 
[98, 135] 
[99] 
[95] 
[91, 92] 
[94, 98] 
[94] 
[91] 
[96, 97] 
a
 Unless indicated, chemokine protein was measured 
b
 The presence or absence of CXCL8, CXCL10, CCL2 and CCL3 mRNA or protein in cells is indicated by + or -, respectively 
Table 5. Cell types responsive to SAA in in vitro (human) and in vivo (mouse) cell migration 
assays 
Target cells 
SAA concentration (µg/ml) or 
dose (µg)a 
References 
monocytes 
1-100 
50 
0.0125-0.125 
0.03-1 
10 (SC, mice) 
50 (SC, mice) 
[108] 
[115] 
[71] 
[83] 
[108] 
[87] 
immature dendritic cells 0.1-1 [83] 
neutrophils 
10-100 
10-50 
1-3 
10 (SC, mice) 
50 (SC, mice) 
3 (SC, mice) 
2 (intranasal, mice) 
1 (IP, mice) 
[108] 
[72] 
[76] 
[108] 
[87] 
[109] 
[110] 
[76] 
T cells 
10-100 
10 (SC, mice) 
[106] 
[106] 
mast cells 12.5 [107] 
endothelial cells 50 [140] 
smooth muscle cells 10-100 [141] 
synovial fibroblasts 10 [142] 
a
 Refers to the SAA concentrations that were found chemotactic for the indicated cell type 
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